The Future of Precision Oncology Starts Here

Dr. Vincent Miller is a world-expert in lung cancer and clinical trial design and interpretation. His role in collaborative research was critical to identifying certain EGFR mutations as the molecular basis of sensitivity and resistance to first-generation EGFR TKIs. Dr. Miller has previously served as Physician-in-Chief at EQRx and prior to that served as Chief Medical Officer at Foundation Medicine. Before joining the Foundation, Dr. Miller dedicated over 20 years to cancer patient care and research at Memorial Sloan Kettering Cancer Center. Among his many accolades, Dr. Miller received the American Cancer Society Clinical Oncology Career Development Award. He joined One’s board in March 2024.

Hedi Ben Brahim was CEO of Transgene from 2021 to 2023. During his tenure, he and his team launched two products in clinic and demonstrated the unique benefits of viral based personalized vaccines in a successful phase 1 program. Prior to that, Hedi was Vice-President, Immunotherapy of Institut Mérieux from 2018 to 2020. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of École Polytechnique and École Nationale Supérieure des Mines de Paris.

Céline Vallot is the head of the Dynamics of Epigenetic Plasticity group at Institut Curie (UMR3244/Translational Department). She joined the Translational Department of IC as a junior group leader in 2017 and is an expert in multi-omics data analysis and epigenetic regulation. She got awarded an ATIP-Avenir grant in 2017, the Bronze Medal of the CNRS in 2018, and the Prix Olga Sain in 2019. Her lab investigates the dynamics of acquisition of chromatin features in cancer cells in vivo and in vitro combining cancer biology to single-cell microfluidics and data mining. Her group has recently co-developed means to analyze the epigenome of cancer cells at single-cell resolution and revealed the heterogeneity of chromatin states within breast tumors. With her group, she has created a series of tools for single-cell data analysis. She has co-founded the single-cell facility of the IC. Céline also holds a MS from Ecole Polytechnique, Paris.

Dr Eric Letouzé, PhD, Head of Single-Cell, has a PhD in Bioinformatics and Cancer Genomics. With deep expertise in cancer genomics and bioinformatics, he has led high-impact teams and projects, including pioneering roles at INSERM and PRAIRIE, where he applied deep learning to uncover cancer-driving alterations. As head of single-cell at One Biosciences, he oversees cutting-edge analyses for clinicians and pharma partners while managing multidisciplinary teams. As co-founder of GeCo, he has also provided advanced genomic consulting, aiding academia and industry in interpreting complex datasets to drive innovation in oncology research.

Romain Letourneur holds a Master’s degree in Competition, Consumer and Intellectual Property Law from the University of Rennes I. He has ten years of legal experience in the biotechnology and life sciences sectors, with expertise spanning strategic contracts, corporate governance, regulatory compliance, and data protection. Prior to joining One Biosciences, he served as Head of Legal & DPO at Home Biosciences and previously held the roles of Senior Manager Legal Affairs, Board Secretary & DPO at DBV Technologies. At One Biosciences, he leads the legal and compliance functions, particularly the structuring of partnerships, corporate governance, and data protection and management issues related to the clinical deployment of the OneMap platform.

Juliette Bertorello holds a PhD in Molecular Biology from Paul Sabatier University (Toulouse). She conducted her doctoral research at the Toulouse Cancer Research Center on mechanisms of glioblastoma resistance, particularly the role of RNA translation and DNA repair proteins in regulating RNA metabolism. She later joined Institut Curie as an R&D engineer, where she developed single-cell protocols and contributed to establishing the first One Biosciences laboratory. At One Biosciences, she leads the laboratory team and oversees the development, optimization, and automation of protocols for generating single-cell, single-nuclei, and multi-omics data. She is notably co-author of a publication in NAR Cancer on translational reprogramming in glioblastoma.

Lars Jorgensen has more than 20 years of international experience in bioinformatics, data science, and large-scale genomic infrastructures. He previously served as Senior Director, Data Science & IT at DNA Script, where he oversaw all Data Science, Bioinformatics, and IT activities, defined the AI strategy (including generative models and LLMs), and led data governance in a regulated environment. Earlier in his career, he led genomic computing activities at the Ontario Institute for Cancer Research (Canada), heading multidisciplinary teams responsible for multi-petabyte sequencing infrastructures and clinical oncology analyses. At One Biosciences, he brings expertise in data architecture, artificial intelligence, and critical systems to build a robust, secure, and scalable platform for the clinical deployment of OneMap.

Raphaëlle Kemoun is a graduate of the ESSEC Business School Grande École program. She worked for more than five years at the Boston Consulting Group (BCG), where she advanced to the position of Project Leader and led high-impact strategic projects for major organizations particularly in the healthcare and technology sectors. She brings strong expertise in growth strategy, operating model design, organizational transformation, and the execution of complex initiatives for pharmaceutical companies and global health institutions. At One Biosciences, she leads strategic planning and the execution of key initiatives, ensuring strong program coordination, clear project prioritization, and close alignment between the company’s scientific vision and its business trajectory.

Vikas Ahuja, Chief Business Officer, is responsible for the development of partnerships with biopharma companies. Vikas brings 20+ years of experience in strategy and business development leadership roles in Life Sciences across Biopharma, Diagnostics and Genomics. He previously led strategic partnerships at Nucleai, an AI driven spatial biology startup, and was formerly Vice President, Business Development & Strategy at Ambry Genetics (now TempusAI). Prior to that he led the International business at Mallinckrodt Pharmaceuticals and previously held corporate and commercial strategy leadership roles at Quest Diagnostics. Vikas holds an MBA from the Wharton School at the University of Pennsylvania, and a Masters in Chemical Engineering from Imperial College, London.